Transglutaminase 2 inhibitor abrogates renal cell carcinoma in xenograft models
- 705 Downloads
To test whether transglutaminase 2 (TGase 2) inhibitor GK921 alone reverses renal cell carcinoma (RCC) tumor growth. RCC is resistant to both radiation and chemotherapy, and the prognosis remains poor. Despite the recent therapeutic success of vascular endothelial growth factor inhibition in RCC, approximately one-third of RCC patients develop metastatic disease. The expression of TGase 2 is markedly increased in most RCC cell lines, as well as in clinical samples.
Previously, we introduced the quinoxaline derivative GK13 as a lead compound for TGase 2 inhibitor. The inhibitory effect of GK13 on TGase 2 was improved in GK921 (3-(phenylethynyl)-2-(2-(pyridin-2-yl)ethoxy)pyrido[3,2-b]pyrazine). GK921 efficacy was tested using sulforhodamine in vitro as well as a xenograft tumor models using ACHN and CAKI-1 RCC cells.
GK921 showed cytotoxicity to RCC (average GI50 in eight RCC cell lines: 0.905 μM). A single treatment with GK921 almost completely reduced tumor growth by stabilizing p53 in the ACHN and CAKI-1 preclinical xenograft tumor models.
TGase 2 inhibitor GK921 abrogates RCC growth in xenograft tumor models, suggesting the possibility of a new therapeutic approach to RCC.
KeywordsTransglutaminase 2 Renal cell carcinoma TGase 2 inhibitor p53
Renal cell carcinoma
NF-κ-B inhibitor α
The study was supported by a research grant (NCC1410280-1) from the National Cancer Center of Korea to S. Y. K. The study was supported by the National R&D Program for Cancer Control (No. 1020050) of Korea to Y. D. G.
Conflict of interest
The authors declare no conflict of interest.
The experiments comply with the current laws of Korea.
- Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH, Sherman PM, Holko M, Yefanov A, Lee H, Zhang N, Robertson CL, Serova N, Davis S, Soboleva A (2013) NCBI GEO: archive for functional genomics data sets-update. Nucl Acids Res 41(Database issue):D991–D995. doi: 10.1093/nar/gks1193 CrossRefPubMedGoogle Scholar
- Delhase M, Kim SY, Lee H, Naiki-Ito A, Chen Y, Ahn ER, Murata K, Kim SJ, Lautsch N, Kobayashi KS, Shirai T, Karin M, Nakanishi M (2012) TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2. Proc Natl Acad Sci USA 109(4):E177–E186. doi: 10.1073/pnas.1119296109 CrossRefPubMedGoogle Scholar
- Hainsworth JD, Waterhouse DM, Penley WC, Shipley DL, Thompson DS, Webb CD, Anthony Greco F (2013) Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI oncology research consortium. Cancer Invest 31(5):323–329. doi: 10.3109/07357907.2013.789900 CrossRefPubMedGoogle Scholar
- Iismaa SE, Holman S, Wouters MA, Lorand L, Graham RM, Husain A (2003) Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases. Proc Natl Acad Sci USA 100(22):12636–12641. doi: 10.1073/pnas.1635052100 CrossRefPubMedPubMedCentralGoogle Scholar
- Kim DS, Choi YB, Han BG, Park SY, Jeon Y, Kim DH, Ahn ER, Shin JE, Lee BI, Lee H, Hong KM, Kim SY (2011a) Cancer cells promote survival through depletion of the von Hippel–Lindau tumor suppressor by protein crosslinking. Oncogene 30(48):4780–4790. doi: 10.1038/onc.2011.183 CrossRefPubMedGoogle Scholar
- Kim SJ, Kim KH, Ahn ER, Yoo BC, Kim SY (2011b) Depletion of cathepsin D by transglutaminase 2 through protein cross-linking promotes cell survival. Amino Acids. doi: 10.1007/s00726-011-1089-6
- Ku BM, Kim DS, Kim KH, Yoo BC, Kim SH, Gong YD, Kim SY (2013) Transglutaminase 2 inhibition found to induce p53 mediated apoptosis in renal cell carcinoma. FASEB J. doi: 10.1096/fj.12-224220
- Lai TS, Liu Y, Tucker T, Daniel KR, Sane DC, Toone E, Burke JR, Strittmatter WJ, Greenberg CS (2008) Identification of chemical inhibitors to human tissue transglutaminase by screening existing drug libraries. Chem Biol 15(9):969–978. doi: 10.1016/j.chembiol.2008.07.015 CrossRefPubMedPubMedCentralGoogle Scholar
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon α in metastatic renal-cell carcinoma. N Engl J Med 356(2):115–124. doi: 10.1056/NEJMoa065044 CrossRefPubMedGoogle Scholar
- Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722–731. doi: 10.1056/NEJMoa1303989 CrossRefPubMedGoogle Scholar